"Private equity is an essential part of the investment landscape, providing capital, expertise, and operational support to businesses. Through our investments, we help build strong, sustainable companies that create jobs, drive economic growth, and deliver value to our investors." - Michael Bleyzer
Our Funds.
Ukrainian Growth Family of Funds
UGF I, II, III
SigmaBleyzer raised $100 million in the mid-90’s and created a family of Ukrainian Growth Funds. UGF I and UGF II began with a diversified portfolio strategy of acquiring minority positions in companies privatized by the Ukrainian government. At the end of 1998, SigmaBleyzer began to shift focus to acquiring majority positions as corporate governance issues grew in importance following the Russian financial crisis. UGF III, which was largely un-invested prior to the Russian Crisis, adopted private equity buyouts as its main strategy. Out of the 84 investments made in the UGF funds by SigmaBleyzer, 19 were private equity buyouts with ownership of at least 25% and effective control of the company. This strategy proved to be the most successful for companies operating in the initial stages of a market economy.
SigmaBleyzer SE European Fund
SBF IV
SBF IV continued the buyout and consolidation strategy of the Ukrainian Growth Family of Funds. Launched in 2006, this €250 million fund invested in Ukraine and Romania as a private equity buyout fund. Four investments were made in cable, agriculture, pharmaceutical retail and dairy production. In all cases, multiple companies were consolidated to create market leaders in each industry. SigmaBleyzer took a hands on approach, making processes more transparent, reducing inefficiencies, improving the management teams, and expanding the businesses of all the portfolio companies held by the fund. SBV IV was well supported by numerous institutional investors, including EBRD and OPIC (now DFC). SBF IV was the first investment made by OPIC since its return to Ukraine in 2010.
MagnaSci Family of Funds
MagnaSci is a family of funds launched in 2016, established to offer a new type of biotechnology fund — a fusion between traditional venture investment and creating value through operational involvement. MagnaSci is focused on creating exceptional returns through reducing the risk of early stage biotechnology investments, concentrating on creating exit opportunities prior to US FDA Phase 2 development, and taking a more involved approach in portfolio company development. The funds primarily target minority investments in companies with experienced management teams at promising early-stage biotech, life science and healthcare ventures in the US that can become commercially viable entities prepared for a strategic exit or IPO.
Co-invests and other investments
In addition to its core investment funds, SigmaBleyzer has provided various co-investment opportunities over the years in numerous sectors, enabling investors to take part in specific opportunities that meet their investment objectives. Other investments have also included General Partner stakes investments, reinvestment of fund capital, pooled investments and funds targeted at other geographical areas, such as Kazakhstan. SigmaBleyzer's diverse range of investment vehicles, coupled with its flexible approach to investing, enables it to provide customized solutions for a wide range of investors looking for unique opportunities, tailored to their specific investment goals.
